Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study | |
Bi, L.; Li, Y.; He, L.; Xu, H.; Jiang, Z.; Wang, Y.; Li, X.; Wei, W.; Gu, J.; Wang, G. | |
刊名 | CLINICAL AND EXPERIMENTAL RHEUMATOLOGY |
2019 | |
卷号 | 37期号:2页码:227-234 |
关键词 | tumour necrosis factor-alpha DMARD certolizumab pegol rheumatoid arthritis Chinese |
URL标识 | 查看原文 |
公开日期 | [db:dc_date_available] |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/4547600 |
专题 | 山东大学 |
作者单位 | 1.Jilin Univ, China Japan Union Hosp, Changchun, Jilin, Peoples R China. 2.Peking Univ, Peoples Hosp, Beijing, Peoples R Chin |
推荐引用方式 GB/T 7714 | Bi, L.,Li, Y.,He, L.,et al. Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY,2019,37(2):227-234. |
APA | Bi, L..,Li, Y..,He, L..,Xu, H..,Jiang, Z..,...&Wu, Z. 更多.(2019).Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.CLINICAL AND EXPERIMENTAL RHEUMATOLOGY,37(2),227-234. |
MLA | Bi, L.,et al."Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study".CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 37.2(2019):227-234. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论